WANBURY LIMITED Share Price

Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.As of 9 Jun 2026, WANBURY LIMITED share price is ₹260.00. The stock opened at ₹255.35, compared to its previous close of ₹252.40. During today's trading session, WANBURY LIMITED share price moved in the range of ₹255.30 to ₹263.50, with an average price of ₹259.40 for the day. Looking at its last 52-week, the stock has touched a low of ₹255.30 and a high of ₹263.50. On the performance front, WANBURY LIMITED share price has increased by 6.75% over the last six months and is down 14.61% on a year-on-year basis.

The market capitalization of WANBURY LIMITED is ₹916 Crs, with a P/E ratio of 20.5 and a dividend yield of 0.00%.